ArticleTranslational vision science & technology2026
Neurosymbolic AI Framework for Explainable Retinal Disease Classification From OCT Images.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Author Response: Using Provenance Dispersion to Triage Uncertain Neurosymbolic OCT Diagnoses.Translational vision science & technology · 2026Article
- Using Provenance Dispersion to Triage Uncertain Neurosymbolic OCT Diagnoses.Translational vision science & technology · 2026Article
- Artificial intelligence for precision therapeutics in age-related macular degeneration: current advances, challenges, and future directions.Frontiers in artificial intelligence · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Accurate classification of retinal diseases such as dry age-related macular degeneration, wet AMD, epiretinal membrane, full-thickness macular hole (MH), lamellar MH, and central serous chorioretinopathy (CSC) is essential for effective treatment and clinical decision-making. Traditional deep learning models, however, often struggle with imbalanced datasets and lack interpretability, limiting their translational applicability in ophthalmology. Methods: We propose a neurosymbolic framework that integrates a convolutional neural network (CNN) with a symbolic reasoning layer based on expert-defined clinical rules. A total of 10,846 optical coherence tomography images were retrospectively collected and categorized into seven diagnostic classes: dry AMD, wet AMD, epiretinal membrane, full-thickness MH, lamellar MH, central serous chorioretinopathy, and healthy retinas. Results: Our neurosymbolic model achieved macro-precision 0.83, recall 0.82, and F1 0.81, on internal dataset, having slightly better performance than the CNN (0.64/0.83/0.68). On the external dataset, it retained superior performance, macro-precision 0.85, recall 0.79, F1 0.78, versus the CNN (0.73/0.64/0.59). Conclusions: Our hybrid neurosymbolic framework introduces a unified paradigm that couples symbolic reasoning with a conventional CNN, improving diagnostic performance while delivering transparent, clinically interpretable decisions. It is particularly effective for rare and complex conditions that often challenge end-to-end deep learning models. Translational Relevance: By integrating symbolic clinical logic with visual pattern recognition, the neurosymbolic model fosters trust in artificial intelligence-assisted diagnostics and supports precise, explainable decision-making in retinal care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.